|
Periaortic VT group
(N=3)
|
Control group
(N=106)
|
P-value
|
Type of aortic valve (mechanical valve) |
2(66) |
58(54) |
1.0 |
Primary aortic valve diseases |
|
|
|
AS |
1(33) |
61(57) |
0.6 |
AR |
1(33) |
27(25) |
1.0 |
IE |
1(33) |
17(16) |
0.4 |
Periods after AVR (years) |
12.3±6.7 |
10.9±8.5 |
0.8 |
Male |
3(100) |
62(58) |
0.3 |
Age (years) |
78.0±3.6 |
73.3±14.1 |
0.6 |
BMI (kg/cm2) |
23.8±2.2 |
22.2±4.2 |
0.5 |
HT |
2(67) |
65(61) |
1.0 |
DL |
2(67) |
51(48) |
0.6 |
DM |
0(0) |
26(24) |
1.0 |
CKD |
2(67) |
53(50) |
1.0 |
Hemodialysis |
0(0%) |
5(5%) |
1.0 |
Medication |
|
|
|
Beta blocker |
2(67) |
60(57) |
1.0 |
ACEI/ARB |
1(33) |
39(37) |
1.0 |
Aldsterone antagonist |
0(0) |
9(8) |
1.0 |
Amiodarone |
1(33) |
6(6) |
0.2 |
Antiarrhythmic drug group 1 |
0(0) |
3(3) |
1.0 |
Paroxysmal atrial fibirillation |
0(0) |
9(8) |
1.0 |
Persistent atrial fibrillation |
0(0) |
16(15) |
1.0 |